BioLabs France

🚀 Reimagine Drug Discovery with Organoids & Lab Automation Are you ready to overcome the biggest challenges in drug discovery and streamline your lab operations? Join us at BioLabs for an inspiring morning with Merck Life Science, where cutting-edge science meets practical solutions you can implement right away. 📅 Date: Tuesday, September 30 ⏰ Time: 10 AM – 1 PM 📍 Location: BioLabs – Hôpital Broussais, 8 rue Maria Helena Vieira Da Silva, 75014, Paris 💡 Focus of the morning: Organoids — the revolutionary tool reshaping translational medicine: 🟢 Organoids: “From Bench to Breakthrough: Harnessing Patient-Derived Organoids (PDO) for Drug Discovery” – Bridge the translational gap and boost your success rate in drug development – Understand why clinical trials fail and how PDOs can turn the tide 🟢 Automation: “No Need to Be a Big Player to Automate Your Lab!” – Automate complex workflows without coding or engineering expertise – Explore plug-and-play solutions for PCR, qPCR, NGS, ELISA, Luminex, protein purification, and more ✨ Why you should attend: Get answers to your toughest lab challenges Discover real, practical solutions you can apply immediately Network with leading scientists and Merck experts over a lunch buffet Register now and secure your spot: [https://lnkd.in/dU4JmS-U] Sylviane BAGHDASSARIAN | Giovanna Fortugno | Natalia Rusyaeva | Véronique Hardouin | Paulina Ejsmont | Anushree Kumar

🚀 We’re hiring! Following our successful €15M Series A, One Biosciences is growing fast — and we’re looking for passionate talents to join our mission to revolutionize cancer diagnostics through single-cell technologies and AI. We currently have 4 open positions in Paris (hybrid): 🔬 Lab Technician – support cutting-edge single-cell and molecular workflows 📊 Project Manager Officer (PMO) – drive execution excellence across science, clinical, and partnerships 💻 Data Engineer – build and optimize our data pipelines powering AI-driven insights 🧪 Research Scientist / Computational Biologist – advance our single cell projects with our partners   If you’re looking to make a real impact in precision oncology and thrive in a dynamic, mission-driven team, we’d love to hear from you!  

🌟 Applications are now open for the Chiesi Air USA Golden Ticket 🌟 In partnership with BioLabs, Chiesi Air USA through the Impulse initiative, is offering a Golden Ticket opportunity at any BioLabs site located in the U.S. Winners will gain free lab space, resources, and access to Chiesi Air USA’s expertise to help accelerate their innovation in respiratory health. If your startup is driving the next breakthrough in respiratory science, this is your chance to take it further with the support of Chiesi Air USA and the BioLabs network. Deadline is September 30th. 👉 Apply now: https://lnkd.in/eRJdxBF8 #BioLabsGoldenTicket BioLabs for Advanced Therapeutics Philadelphia | BioLabs Greater Boston | BioLabs New Haven | Princeton Innovation Center BioLabs | Biolabs@NYULangone | BioLabs Pegasus Park - North Texas | BioLabs Innovation Center at University of Vermont | BioLabs North Carolina | BioLabs San Diego | BioLabs at The Lundquist Institute

🏃♀️🏃🏼 Contre les cancers pédiatriques, chaussez vos baskets le 28 septembre prochain pour la 14e édition de la course Enfants sans Cancer organisée par l’association Imagine for Margo - Children without Cancer ! Ensemble, donnons un espoir de guérison à tous les enfants et adolescents atteints de cancer : 100% des dons collectés par les participants de la course Enfants sans Cancer sont affectés à la recherche pour aider les chercheurs à mieux comprendre et à mieux soigner les cancers des enfants. Un évènement solidaire à ne pas manquer auquel vous pouvez participer seul(e) ou en équipe, en courant ou en marchant, à Saint-Cloud ou en connecté ! Inscrivez-vous dès maintenant sur 👉 enfantssanscancer.com

We’re proud to announce the launch of BioLabs | TUM: a new innovation hub opening end of 2025, in partnership with TUM Venture Labs and Lilly Deutschland GmbH.   With 1,800 sqm of fully equipped labs and offices, BioLabs | TUM will support 15–20 early-stage biotech startups by combining world-class infrastructure with tailored mentorship and access to global scientific and venture networks.   But what truly sets this project apart is the partnership behind it: 🔹 BioLabs, bringing its proven coworking lab model to Munich 🔹 TUM Venture Labs, translating cutting-edge science into scalable ventures 🔹 Lilly Deutschland GmbH, advancing early innovation through its Catalyze360™ model   Together, we’ve crafted a space where biotech startups will have the infrastructure, community, and connections they need to bring the next wave of therapies to life.   📖 Curious about the full story? 👉 https://lnkd.in/eGAg6_s2   More than a facility, it’s a shared mission — powered by people driving real change in biotech: Johannes Fruehauf | Philipp Gerbert | Johanna Michielin | Clément Lapierre | Giulia Mariatti | Valentina Zaburunova | Miriam Becker | Maria Sievert | Verena Stocker | Dr. Nicolai Heinzelmann | Katrin Blank | Chris Railey | Jasmin Eigemann   #BioLabsTUM #BuiltForBiotech #MunichInnovation #LifeSciences #DeepTechGermany #LillyCatalyze360 #TUMVentureLabs #StartupEcosystem #BioLabsEurope #Biotech #Innovation

🎉 New faces, new ideas at Spartners by Servier & BioLabs! We’re excited to welcome five innovative biotech startups to our community: - Dio Tree – Advancing first-in-class small molecules targeting the DIO3 enzyme in high-grade serous ovarian cancer, backed by strong preclinical data. - BioUs Biotech – Developing next-generation bioproduction tools to accelerate innovation in cell and gene therapy. - EG 427  – Pioneering precision gene therapies using a non-replicative HSV‑1 vector platform for chronic neurological diseases, with lead candidate in clinical development. - ZebraMed – Harnessing zebrafish models, robotics, and AI to improve predictive power and efficiency in drug discovery. - Cor.Sync – Delivering high-precision, point-of-care troponin tests with lab-grade accuracy in just eight minutes to revolutionize heart attack diagnosis. We’re honored to support their missions and can’t wait to see the breakthroughs ahead. Welcome on board! 🚀 👉 If you’re a biotech startup looking to grow in a dynamic, collaborative, and cutting-edge environment, we’d love to hear from you! Hélène Sire Jean-Roch Llense Stelina Loiodice Anais Ralimbimanana Celine Triquel Nadia Benallal Raimundo Silva Jr Dr. Sarit Batsir Mikael Contrastin Lorenzo Zolfanelli Raul de Macedo

So, so happy for you all at One Biosciences! 💫 Your €15M Series A marks a strong vote of confidence in your vision and the platform you're building to bring single-cell technologies into the clinic. As you move forward with bringing OneMap™ into the clinic and deepening partnerships with pharma and biotech companies, know that we’re here to support you. Connecting startups with the right players is at the heart of what we do at BioLabs, and we’re always glad to explore the right opportunities alongside you. Can’t wait to see what’s next. 🙌 Hedi Ben Brahim

🏙️ Eiffel Tower views. A bold new HQ. And a shared commitment to innovation. On the occasion of Ipsen’s new Paris HQ inauguration, Johanna Michielin, Europe Director at BioLabs, spoke about the deep impact of our partnership; one that helped launch the BioLabs Hôtel-Dieu site two years ago. Today, over 30 biotech startups are accelerating science from the heart of Paris, supported by strategic guidance and scientific expertise from Ipsen. 💬 “Built around well-being, collaboration and inclusivity…” — Ipsen’s new HQ isn’t just a beautiful space with iconic views, it reflects the values that power our ecosystem. From idea to impact, we’re proud to walk this path together. Johannes Fruehauf | Johanna Michielin | Christophe Tallec | David Loew | Christelle Huguet | Laurent Bertocchi | Pierre-Frédéric Billet | Christophe Heriard | Olivier Marleix | Gerard Sourisseau | Catherine George | Florence Dal Degan | Benjamin Boiseau | Mehdi ZOUAOUI #Ipsen #BioLabs #LifeSciences #BiotechInnovation #ParisHQ #StartupSupport #PharmaInnovation #EiffelTowerViews #CollaborationMatters #FromBenchToBedside

🥁 Announcing the Four Finalists for the 2025 Ipsen #GoldenTicket We are proud to unveil the four startups selected as finalists for the 2025 Ipsen Golden Ticket, a program offering one year of free lab and office space at BioLabs Hôtel-Dieu, right in the heart of Paris. Each finalist embodies scientific excellence and bold ambition, tackling some of the most urgent challenges in human health: 🧬 StarkAge Therapeutics Senescent cells build up in tissues as we age, contributing to cancer, fibrosis, and other chronic diseases. StarkAge is developing antibody-drug conjugates that selectively eliminate these cells. Their approach could change how we treat cancer and age-related disease at its root. 🧪 DETERA Therapeutics People with crescentic glomerulonephritis often end up on dialysis within months of diagnosis. Detera is working on an innovative peptide therapy that acts earlier, protecting kidney function before damage becomes irreversible. It’s a new way of thinking about intervention in rare kidney disease. 💊 InFocus Therapeutics RNA splicing errors drive many cancers and neurological diseases, but drugging them has been a major challenge. InFocus is building orally available small molecules that target these errors with precision. Their work could finally make RNA splicing a practical target in the clinic. 🧠 CLOVERNA Most discovery platforms overlook non-coding RNA, even though that’s where most disease-linked mutations occur. CLOVERNA’s platform identifies functional non-coding RNA targets directly in disease models. Their lead program targets TDP-43 aggregation in ALS, seen in the majority of patients. 🙏 Thanks to the jury members for their thoughtful involvement Emily Fang | Lyse Santoro | Benjamin LeCalvé | Tatsuo Ito | Catherine George | Florence Dal Degan | Benjamin Boiseau | Mehdi ZOUAOUI